source
- STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatmentProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
- GSK shares rise as $2.5B cost-cutting plan unveiledAs GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.